Default company panoramic image
4bd78339 0fbe 4fde b180 a5245d1a5e6a

Aursos, Inc.

Aursos is developing a synthetic bone graft that is safer and more effective than current options for spine fusion and other bone repairs.

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Kalamazoo, MI, USA
  • Currency USD
  • Founded January 2008
  • Employees 2
  • Website

Company Summary

Aursos is developing a synthetic bone graft for spinal fusions and other orthopedic indications. The Company's proprietary parathyroid hormone (PTH) peptide AUR84 produces robust and safe bone growth and is combined with a resorbable bone cement to create the bone-like implant. This product provides orthopedic surgeons an easier and safer alternative to donor site bone grafts or BMP products that are associated with serious complications.


  • Default avatar
    Kristyn Rene Aalto
    President and CEO

    Ms. Aalto, Aursos President and CEO, joined Aursos in 2012 after serving as President of Accord BIosciences for three years. Prior to Accord, Ms. Aalto was the Coulter Translational Research Director at UM and an Entrepreneur in Residence with Arboretum Ventures. She has significant orthopedics industry experience including synthetic bone graft development and securing multiple FDA product clearances from previous roles with Stryker and Inion.

  • Default avatar
    Ronald J. Shebuski

    Dr. Shebuski has over 25 years' experience in the pharmaceutical industry and served as the Director of Cardiovascular Therapeutics at Pharmacia & Upjohn in Kalamazoo, MI from 1990-1998. He established a Cardiovascular Research Consulting Firm in 1998 and continues to serve small, mid and large pharma in many aspects of drug discovery and development.


  • Default avatar
    Kara Hoorn, Honigman, Kalamazoo
    Default avatar
    Terry Lewis

Previous Investors

  • Default avatar
    Default avatar
    Ann Arbor Spark
    Default avatar